Serum MicroRNA-181a Expression Level in Patients with Acute Liver Failure and Its Correlation with Prognosis

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2024 Oct 23

PMID 39440101

Authors

Lili Wang

Pingping Liu

Yidi Han

Affiliations

Soon will be listed here.

Abstract

Objective: This paper examined miR-181a expression in the serum of patients with acute liver failure (ALF) and investigated the impact of its expression in the prognosis of ALF patients.

Methods: A total of 112 ALF patients (ALF group) and 100 healthy controls during the same period (control group) were recruited as study subjects, and ALF patients were separated into the survival group and the death group. Serum ALT, AST, SCr, TBil, PTA, and International Normalized Ratio (INR) indices as well as serum miR-181a expression were assessed by using a fully automated biochemistry analyzer and RT-qPCR. Patients in the ALF group were evaluated using the Model for End-Stage Liver Disease (MELD) score. Correlation between serum miR-181a expression and MELD scores of ALF patients was processed by Pearson correlation analysis, and the diagnostic value of miR-181a level for the occurrence of ALF was estimated by ROC curve analysis. Multivariate logistic regression analysis was executed to assess the factors influencing the occurrence of death in ALF patients.

Results: ALF patients had higher levels of ALT, AST, TBiL, SCr, INR and miR-181a and lower PTA levels in comparison to healthy controls. Serum miR-181a expression level in ALF patients revealed a significant positive correlation with MELD score. Multivariate logistic regression analysis unveiled that TBil, INR, SCr, and miR-181a were the independent risk factors for the occurrence of death in ALF patients, and that PTA was an independent protective factor for the prognosis of ALF patients. miR-181a exhibited a favorable diagnostic value in ALF and its prognosis.

Conclusion: miR-181a expression is upregulated in the serum of ALF patients, and it can be utilized as an indicator for ALF diagnostic and prognostic assessment.

Citing Articles

Role of Decreased Expression of miR-155 and miR-146a in Peripheral Blood of Type 2 Diabetes Mellitus Patients with Diabetic Peripheral Neuropathy [Letter].

Akollo I Diabetes Metab Syndr Obes. 2025; 18():113-114.

PMID: 39811704 PMC: 11730505. DOI: 10.2147/DMSO.S510822.

Serum microRNA-181a Expression Level in Patients with Acute Liver Failure and Its Correlation with Prognosis [Letter].

Akollo I Int J Gen Med. 2024; 17:5247-5248.

PMID: 39554872 PMC: 11569702. DOI: 10.2147/IJGM.S503175.

References

Trehanpati N, Sehgal R, Patra S, Vyas A, Vasudevan M, Khosla R . miRNA signatures can predict acute liver failure in hepatitis E infected pregnant females. Heliyon. 2017; 3(4):e00287. PMC: 5384411. DOI: 10.1016/j.heliyon.2017.e00287. View

Squires J, McKiernan P, Squires R . Acute Liver Failure: An Update. Clin Liver Dis. 2018; 22(4):773-805. DOI: 10.1016/j.cld.2018.06.009. View

Ji J, Yamashita T, Budhu A, Forgues M, Jia H, Li C . Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology. 2009; 50(2):472-80. PMC: 2721019. DOI: 10.1002/hep.22989. View

Montrief T, Koyfman A, Long B . Acute liver failure: A review for emergency physicians. Am J Emerg Med. 2018; 37(2):329-337. DOI: 10.1016/j.ajem.2018.10.032. View

van Caster P, Brandenburger T, Strahl T, Metzger S, Bauer I, Pannen B . Circulating microRNA-122, -21 and -223 as potential markers of liver injury following warm ischaemia and reperfusion in rats. Mol Med Rep. 2015; 12(2):3146-50. DOI: 10.3892/mmr.2015.3742. View

Zhuang X, Chen Y, Wu Z, Xu Q, Chen M, Shao M . Mitochondrial miR-181a-5p promotes glucose metabolism reprogramming in liver cancer by regulating the electron transport chain. Carcinogenesis. 2019; 41(7):972-983. DOI: 10.1093/carcin/bgz174. View

Du X, Yang Y, Xu C, Peng Z, Zhang M, Lei L . Upregulation of miR-181a impairs hepatic glucose and lipid homeostasis. Oncotarget. 2017; 8(53):91362-91378. PMC: 5710930. DOI: 10.18632/oncotarget.20523. View

Wen Y, Peng S, Fu L, Fu X, Wu D, Liu B . Serum levels of miRNA in patients with hepatitis B virus-associated acute-on-chronic liver failure. Hepatobiliary Pancreat Dis Int. 2018; 17(2):126-132. DOI: 10.1016/j.hbpd.2018.03.004. View

Loosen S, Schueller F, Trautwein C, Roy S, Roderburg C . Role of circulating microRNAs in liver diseases. World J Hepatol. 2017; 9(12):586-594. PMC: 5411953. DOI: 10.4254/wjh.v9.i12.586. View

10.

Arshad M, Murphy N, Bangash M . Acute liver failure. Clin Med (Lond). 2020; 20(5):505-508. PMC: 7539708. DOI: 10.7861/clinmed.2020-0612. View

11.

Starkey Lewis P, Dear J, Platt V, Simpson K, Craig D, Antoine D . Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology. 2011; 54(5):1767-76. DOI: 10.1002/hep.24538. View

12.

Shingina A, Mukhtar N, Wakim-Fleming J, Alqahtani S, Wong R, Limketkai B . Acute Liver Failure Guidelines. Am J Gastroenterol. 2023; 118(7):1128-1153. DOI: 10.14309/ajg.0000000000002340. View

13.

Ye Q, Huang J, Xu Z, Yan Y, Yan Y, Liu L . Short-term prognostic factors for hepatitis B virus-related acute-on-chronic liver failure. World J Clin Cases. 2022; 10(23):8186-8195. PMC: 9403684. DOI: 10.12998/wjcc.v10.i23.8186. View

14.

Li Q, Chau J, Ebert P, Sylvester G, Min H, Liu G . miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 2007; 129(1):147-61. DOI: 10.1016/j.cell.2007.03.008. View

15.

Blaya D, Pose E, Coll M, Lozano J, Graupera I, Schierwagen R . Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure. JHEP Rep. 2021; 3(2):100233. PMC: 7902550. DOI: 10.1016/j.jhepr.2021.100233. View

16.

Salehi S, Tavabie O, Verma S, McPhail M, Farzaneh F, Bernal W . Serum MicroRNA Signatures in Recovery From Acute and Chronic Liver Injury and Selection for Liver Transplantation. Liver Transpl. 2020; 26(6):811-822. DOI: 10.1002/lt.25781. View

17.

Krauskopf J, Caiment F, Claessen S, Johnson K, Warner R, Schomaker S . Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury. Toxicol Sci. 2014; 143(2):268-76. DOI: 10.1093/toxsci/kfu232. View

18.

Rakela J, Karvellas C, Koch D, Vegunta S, Lee W . Acute Liver Failure: Biomarkers Evaluated by the Acute Liver Failure Study Group. Clin Transl Gastroenterol. 2023; 14(4):e00565. PMC: 10132708. DOI: 10.14309/ctg.0000000000000565. View

19.

McPhail M, Farne H, Senvar N, Wendon J, Bernal W . Ability of King's College Criteria and Model for End-Stage Liver Disease Scores to Predict Mortality of Patients With Acute Liver Failure: A Meta-analysis. Clin Gastroenterol Hepatol. 2015; 14(4):516-525.e5. DOI: 10.1016/j.cgh.2015.10.007. View

20.

Wang Y, Mou Q, Zhu Z, Zhao L, Zhu L . MALAT1 promotes liver fibrosis by sponging miR‑181a and activating TLR4‑NF‑κB signaling. Int J Mol Med. 2021; 48(6). PMC: 8547543. DOI: 10.3892/ijmm.2021.5048. View